Immix Biopharma, Inc. Common Stock
$12.14
-$0.07 (-0.57%)
$11.81Day Range$12.63
Key Statistics
Market Cap
$873.50M
Shares Outstanding
71.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Dec 16, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$12.49
Day High
$12.63
Day Low
$11.81
Volume
1.05M
VWAP
$12.11
Prev Close
$12.21
Transactions
--
Acc. Volume
--
About Immix Biopharma, Inc. Common Stock
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
PHARMACEUTICAL PREPARATIONSSIC 283421 employees11400 WEST OLYMPIC BLVD., LOS ANGELES, CA, 90064(888) 958-1084IPO Dec 16, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001873835
- Composite FIGI
- BBG00HLCWH09
- Share Class FIGI
- BBG00HLCWH18
- Ticker Root
- IMMX
- SIC Code
- 2834
About Immix Biopharma, Inc. Common Stock (IMMX) Stock
Immix Biopharma, Inc. Common Stock (IMMX) closed the 2026-09-15 session at $12.14, down 0.57% versus the previous close (-0.07). The stock opened at $12.49 and traded between $11.81 and $12.63 during that session. Session trading volume was 1.1M shares. The volume-weighted average price (VWAP) is $12.11.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Immix Biopharma, Inc. Common Stock has a market capitalization of $873.5 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. IMMX is listed on the XNAS exchange. The company employs approximately 21 people. Immix Biopharma, Inc. Common Stock is headquartered in LOS ANGELES, CA. The recorded listing date is 2021-12-16.
On this page you can find market IMMX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.